SMITH J. JEFFERSON 4

What Happened

• Smith J. Jefferson, Chief Research Officer of Precision BioSciences (DTIL), had Restricted Stock Units (RSUs) vest and convert into common shares on Feb 17, 2026. The Form 4 reports an exercise/conversion of 16,667 RSU-derived shares (reported at $0.00) tied to that vesting. The filing also shows an open-market sale on Feb 18, 2026 of 4,925 shares at $3.84 per share, generating $18,912 in proceeds. Footnotes indicate the transactions relate to RSU vesting and settlement.

Key Details

• Dates & prices:
  • Feb 17, 2026: conversion/settlement of RSUs (16,667 shares reported as acquired at $0.00; a related derivative disposition of 16,667 shares is also reported).
  • Feb 18, 2026: open-market sale of 4,925 shares at $3.84 — proceeds $18,912.
• Purpose/footnotes: Sales were effected under a Rule 10b5-1 plan as a sell-to-cover to satisfy tax withholding on RSU vesting (Reporting Person states shares were sold only to cover required taxes and fees).
• Shares owned after transaction: Not disclosed in the provided summary of this Form 4.
• Timeliness: Filing covers the Feb 17, 2026 vesting and was filed Feb 19, 2026 (appears timely).

Context

• RSUs are awards that convert to shares upon vesting; this was a routine vesting/settlement event rather than a voluntary investment or market-timed sale. The small open-market sale was to cover withholding taxes and is generally viewed as administrative rather than a signal about company prospects. Purchases by insiders are typically more informative about sentiment than sell-to-cover transactions.